Welcome to our dedicated page for Coya Therapeutics news (Ticker: COYA), a resource for investors and traders seeking the latest updates and insights on Coya Therapeutics stock.
Coya Therapeutics, Inc. (NASDAQ: COYA) is a clinical-stage biotechnology company headquartered in Houston, Texas, with news flow centered on its regulatory T cell (Treg)–focused pipeline for neurodegenerative and inflammation-driven diseases. Company updates frequently highlight progress with COYA 302, an investigational proprietary biologic combination of low-dose interleukin-2 (LD IL-2) and CTLA-4 Ig, and COYA 303, an investigational combination of LD IL-2 and a GLP-1 receptor agonist.
Investors following COYA news can expect regular coverage of clinical trial milestones, including the Phase 2 ALSTARS Trial of COYA 302 in amyotrophic lateral sclerosis (ALS). Coya has announced key events such as FDA acceptance of its IND for COYA 302 in ALS, Health Canada’s acceptance of a Clinical Trial Application, initiation and dosing of patients in the ALSTARS Trial, and milestone payments received under its Development and License Agreement with Dr. Reddy’s Laboratories Ltd.
News items also describe regulatory developments for frontotemporal dementia (FTD), including FDA acceptance of an IND for COYA 302 in FTD and results from an investigator-initiated open-label study of low-dose IL-2 and CTLA4-Ig in FTD patients. Additional releases cover preclinical data for COYA 303 in an in vivo model of systemic and neurologic inflammation, corporate financing activities such as an upsized public offering of common stock, and quarterly financial results and corporate updates.
This COYA news page aggregates these disclosures so readers can review clinical, regulatory, scientific, and financing announcements in one place. For those tracking Treg-based approaches to ALS, FTD, Alzheimer’s disease, and related conditions, the news stream provides direct access to Coya’s reported data, trial status updates, and key corporate events over time.
Coya Therapeutics (NASDAQ: COYA), a clinical-stage biotech company focused on developing biologics for regulatory T cell function enhancement, announces its participation in the H.C. Wainwright 3rd Annual BioConnect Conference on May 20, 2025. CEO Arun Swaminathan will engage in a fireside chat at 12:30pm ET at the Nasdaq World Headquarters in New York City.
The presentation will be available via webcast, with management offering one-on-one meeting opportunities. The webcast will be accessible through Coya's website and remain available for 90 days after the event.
Coya Therapeutics (NASDAQ: COYA), a clinical-stage biotech company focused on developing biologics for regulatory T cell function enhancement, has announced its participation in two upcoming conferences in May 2025. The company's leadership, including CEO Dr. Arun Swaminathan and CFO David Snyder, will be available for one-on-one meetings with registered investors at:
1. The D. Boral Capital Inaugural Global Conference on May 14, 2025, at The Plaza Hotel in New York
2. The Mizuho Neuro & Opthalmology Summit from May 20-21, 2025, at the Park Lane Hotel in New York
Coya Therapeutics (NASDAQ: COYA) has announced positive interim results from an investigator-initiated open-label study testing low-dose IL-2 and CTLA4-Ig combination treatment in Frontotemporal Dementia (FTD) patients. The study, conducted at Houston Methodist Neurological Institute, showed promising results in the first cohort of 5 patients.
Key findings include:
- Statistically significant increase in Treg numbers and suppressive function
- Minimal to no cognitive decline throughout the study period
- Well-tolerated treatment with no serious adverse events
- All 5 patients completed the 22-week treatment course
This is particularly notable as FTD patients typically experience rapid cognitive decline, with historical data showing an average 3.57-point worsening over 12 months on the CDR-FTLD scale. The treatment's success in maintaining cognitive function suggests potential therapeutic value for FTD, which currently has no approved treatments.
Coya Therapeutics (NASDAQ: COYA) has published research results for COYA 303, a novel biologic combination of low-dose interleukin 2 (LD IL-2) and GLP-1 receptor agonist (GLP-1RA), designed to enhance regulatory T cell (Treg) function in autoimmune and neurodegenerative diseases.
The study, conducted at Houston Methodist Research Institute, demonstrated that COYA 303 achieved a 42% increase in Treg suppressive function, significantly outperforming individual components (LD IL-2 at 15% and GLP-1RA at 20%). The combination therapy also showed enhanced Treg survival through reduced BAX transcript levels and inhibition of Treg apoptosis.
The research suggests COYA 303 could offer a differentiated approach for conditions like Alzheimer's Disease, where GLP-1 RAs have shown promise, by combining anti-inflammatory effects with enhanced Treg survival and function.
Coya Therapeutics (NASDAQ: COYA), a clinical-stage biotechnology company focused on regulatory T cell (Treg) function enhancement, has announced an upcoming presentation at the ADPD 2025 conference in Vienna.
Principal Investigator Dr. Alireza Faridar from Houston Methodist Hospital will present progress updates on a Phase II clinical trial investigating low-dose IL-2 treatment in patients with mild to moderate Alzheimer's disease. The presentation is scheduled for April 5, 2025.
Coya Therapeutics (NASDAQ: COYA) provided an update on its Treg-derived exosome platform development for treating systemic and neurodegenerative diseases. The company's research has shown that regulatory T cell-derived exosomes (Treg exosomes) effectively suppress inflammation in preclinical models.
Key developments include:
- Treg exosomes demonstrated strong therapeutic potential in suppressing inflammation in neurodegenerative disease models
- Initial engineering batches using healthy donor Tregs planned for Q1 2025
- GMP manufacturing of larger-scale clinical batches scheduled for Q4 2025
- Program funded by Johnson Center for Cellular Therapeutics, Hop On A Cure, and Energy Transfer
The company highlighted that Treg exosomes have advantages over Tregs as they target myeloid cells driving disease progression and resist conversion to non-suppressive phenotypes in inflammatory environments.
Coya Therapeutics (NASDAQ: COYA) has reported its fiscal 2024 results and corporate updates. The company ended 2024 with $38.3 million in cash and reported a net loss of $14.9 million, compared to $8.0 million in 2023.
Key financial achievements include raising $10.0M through private placement, receiving a $5.0M strategic investment from the Alzheimer's Drug Discovery Foundation, and securing $3.85M from Dr. Reddy's Laboratories.
R&D expenses increased to $11.9 million in 2024 from $5.5 million in 2023, while G&A expenses rose to $8.9 million from $7.8 million.
The company announced positive results from Phase 2 studies in Alzheimer's disease and progress in Frontotemporal Dementia trials. Key upcoming catalysts for 2025 include submission of COYA-302 Phase 2 trial data for ALS treatment, potential milestone payments of $8.4M, and various data publications across their pipeline.